蛋白芯片技术联合定量检测妇科肿瘤标志物的研究  

Combined detection of multiple biomarkers in gynecological tumors by protein chip technology

作　　者：何宝贤 陈姝[3] 刘芳[2] 蒋泓[2] 冯翠兰[2] 唐冬生[2] 

机构地区：[1]佛山市禅城区中心医院检验科,广东佛山528000 [2]佛山科学技术学院基础医学部,广东佛山528000 [3]佛山市第一人民医院检验科,广东佛山528000

出　　处：《佛山科学技术学院学报（自然科学版）》2014年第6期41-45,共5页Journal of Foshan University(Natural Science Edition)

基　　金：国家自然科学基金资助项目(81272552);广东省高科技发展专项资金资助(2012A030400066)

摘　　要：目的研究C12联合检测多种肿瘤标志物对妇科恶性肿瘤诊断的意义。方法选取100例妇科良性病变、73例健康女性和病理确诊的81例妇科恶性肿瘤(卵巢癌、子宫颈癌、子宫内膜癌)病例的血清标本,利用HD-2001A蛋白芯片仪进行12种肿瘤标志(包括CA199,NSE,CEA,CA242,CA125,CA153,AFP,Ferritin,Free-PSA,PSA,HGH andβ-HCG)的联合定量检测,对比C12芯片检测系统检测妇科恶性肿瘤与良性病变及正常对照组的差异性。结果妇科恶性肿瘤组中CA199、CEA水平及阳性率均高于良性病变组和正常对照组,统计学差异显著(p<0.05)。卵巢癌中CA199和CA125、子宫颈癌和子宫内膜癌中CEA水平高于正常对照组,差异有显著性(p<0.05)。卵巢癌中CA199和CA125联合检测能提高阳性率。结论利用C12联合检测多种肿瘤标志物可以提高恶性肿瘤诊断的准确性,其中卵巢癌中CA199和CA125、子宫颈癌和子宫内膜癌中CEA肿瘤标志物蛋白芯片检测对筛查妇科肿瘤高危人群具有重要意义。The present study aims to explore the significance of the combined detection of multiple serum tumor-markers using protein biochip technique in patients with gynecological tumors. The serum levels of 12 tumor markers, including CA19-9, NSE ,CEA, CA242 ,CA125, CA153, AFP, ferritin, free-PSA, PSA, HGH and β-HCG were measured using the multiple-tumor marker protein chip system （HD-2001A） in 81 cases of gynecologic tumors（including ovarian cancer, cervical cancer, endometrial cancer）, 100 cases of benign lesions and 73 cases of healthy adults. The differences among the gynecological malignancy group, benign lesions group and normal control group were analyzed. The serum levels and positive rates of CEA and CA199 in patients with gynecological malignancy were significantly higher than those in patients with benign lesions and healthy adults （p〈 0.05）. The serum levels of CA199 and CA125 in cases with ovarian cancer were significantly higher than those of the normal control group（p〈0.05）, and the serum levels of CEA in cases with uterine cervical cancer and endometrial carcinoma were also significantly higher than those of the normal control group（p〈0.05）. The combined detection of CA199 and CA125 can improve the positive rate of ovarian cancer. Combined detection of multiple serum tumor-markers using protein biochip technology can significantly increase the diagnostic sensitivity for gynecological malignancy. The combined detection of CA199 and CA125 play important roles in the positive detective rates in population with high risk of gynecological malignancy.

关 键 词：妇科肿瘤 标志物 蛋白芯片 分子诊断 

分 类 号：R737.3[医药卫生—肿瘤]